Lilly and Amgen - Major Expansions of US Manufacturing Sites
Lilly will invest $3 billion in its newly purchased Wisconsin manufacturing site, and Amgen will invest $1 billion in North Carolina.
Companies Amgen of Holly Springs, North Carolina, and Eli Lilly and Company (Lilly) of Kenosha County, Wisconsin, have each declared intentions to increase production capacity. Amgen has announced a $1 billion investment to build a second drug substance manufacturing facility at its Holly Springs site, bringing the total planned investment in Holly Springs to more than $1.5 billion. Lilly, on the other hand, announced a $3 billion investment to expand the Kenosha County manufacturing facility it acquired earlier in 2024.
In order to keep up with the increasing demand for its diabetes and obesity treatments and future pipeline medicines across therapeutic categories, Lilly is investing to expand the company's worldwide parenteral product production network. The anticipated start year for the expansion's construction is 2025. In addition to the 100 or so people already employed by Lilly in Kenosha County, the company plans to hire an additional 750 highly qualified individuals. There will be about 2,000 new construction jobs created during the project, and there will also be new highly skilled occupations including operators, technicians, engineers, and scientists.
According to Edgardo Hernandez, executive vice-president and president of Lilly Manufacturing Operations, "Today's announcement represents our single largest US manufacturing investment outside our home state of Indiana and will add to our ability to expand capacity to make both our existing and future pipeline of medicines right here in the Midwest." This statement was made in a company press release. "We look forward to bringing high-wage, advanced manufacturing, engineering, and science jobs to people in Wisconsin, a state that is becoming a critical geography in our global manufacturing operations."
Injectable medication production will be accelerated by Lilly using modern automation, which includes guided trucks, robots, and industrial equipment. Data management and operations will both benefit from digital automation's ability to speed up procedures and improve accuracy.
In Wisconsin, Lilly is committed to advancing innovation in pharmaceutical production through partnering with local universities and supporting community projects.
With their investment in the Holly Springs property, Amgen will construct a new drug substance manufacturing facility. The growth will include the incorporation of state-of-the-art technology and environmentally conscious procedures. In addition to bolstering the site's current facilities, the company's expenditures will generate 370 new job opportunities in the area and establish a strong biomanufacturing cluster.
"This expansion underscores our unwavering focus on bringing transformative medicines to patients around the world," said Robert A. Bradway, chairman and the executive officer at Amgen, in a joint statement with the press. "North Carolina will be an important part of our global manufacturing network as we continue to meet the growing demand for our innovative therapies while generating significant local economic impact."
The North Carolina ecosystem of life sciences innovation and competent workforce were major factors in Amgen's decision to locate in the state, which has become known as a leading location for life sciences. The release from the company added that this expansion will strengthen their global biomanufacturing network. It will use their operational knowledge and technology improvements to guarantee the efficient and dependable delivery of high-quality medications to patients all around the world.
Source: Eli Lilly and Company, Amgen
